In agreement with several lines of evidence from various cancers [79], our study demonstrates that KMT2C acts invariably as a tumour suppressor in breast cancer, since tumours that lack KMT2C became palpable significantly earlier than the WT counterparts. The gene discussed is KMT2C; the disease is neoplasm.